The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Editorial

Are all DES equal at 10-year follow-up?

EuroIntervention 2019;15:e945-e947. DOI: 10.4244/EIJV15I11A176

1. Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland


The evolution of stent technology has witnessed major breakthroughs during the past three decades. Early-generation drug-eluting stents (DES) releasing sirolimus (sirolimus-eluting stents [SES], e.g., CYPHER®; Johnson & Johnson, New Brunswick, NJ, USA) or paclitaxel (paclitaxel-eluting stents [PES], e.g., TAXUS™; Boston Scientific, Marlborough, MA, USA) reduced the risk of restenosis and repeat revascularisation compared with bare metal stents (BMS). However, the improved efficacy was offset by the increased risk of very late stent thrombosis (ST) and delayed repeat revascularisation owing to impaired arterial healing and neoatherosclerosis attenuating the risk-benefit profile during longer-term follow-up. The Endeavor® ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
FFR for CABG: not ready for prime time